Sienna Biopharmaceuticals (Sienna Biopharmaceuticals) Cash, Cash Equivalents, Marketable Securities : $11.33 Mil (As of Sep. 2019)

View and export this data going back to 2017. Start your Free Trial

What is Sienna Biopharmaceuticals Cash, Cash Equivalents, Marketable Securities?

Sienna Biopharmaceuticals's quarterly cash, cash equivalents, marketable securities declined from Mar. 2019 ($57.17 Mil) to Jun. 2019 ($49.21 Mil) but then stayed the same from Jun. 2019 ($49.21 Mil) to Sep. 2019 ($11.33 Mil).

Sienna Biopharmaceuticals's annual cash, cash equivalents, marketable securities increased from Dec. 2016 ($9.09 Mil) to Dec. 2017 ($74.47 Mil) but then declined from Dec. 2017 ($74.47 Mil) to Dec. 2018 ($48.53 Mil).

Sienna Biopharmaceuticals Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Sienna Biopharmaceuticals's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sienna Biopharmaceuticals Cash, Cash Equivalents, Marketable Securities Chart

Sienna Biopharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Cash, Cash Equivalents, Marketable Securities

4.96

9.09

74.47

48.53

Sienna Biopharmaceuticals Quarterly Data
	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19
Cash, Cash Equivalents, Marketable Securities	Get a 7-Day Free Trial											63.98	48.53	57.17	49.21	11.33

Sienna Biopharmaceuticals Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Sienna Biopharmaceuticals (OTCPK:SNNAQ) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Sienna Biopharmaceuticals Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Sienna Biopharmaceuticals's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Sienna Biopharmaceuticals (Sienna Biopharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sienna Biopharmaceuticals Inc (OTCPK:SNNAQ) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

Traded in Other Exchanges

N/A

Address

30699 Russell Ranch Road, Suite 140, Westlake Village, CA, USA, 91362

Website

http://www.SiennaBio.com

Sienna Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on bringing innovations in biotechnology to the discovery, development, and commercialization of first-in-class, targeted, topical products in medical dermatology and aesthetics. The objective is to develop multi-asset pipeline of topical therapies that enhance the health, appearance, and quality of life of dermatology patients. The product portfolio includes SNA-120, SNA-125, and SNA-001.

Executives

Alexander Azoy	officer: Chief Financial Officer	30699 RUSSELL RANCH ROAD, SUITE 140, WESTLAKE VILLAGE CA 91362
Timothy K. Andrews	officer: General Counsel & Secretary	30699 RUSSELL RANCH ROAD, SUITE 140, WESTLAKE VILLAGE CA 91362
Iii Frederick Beddingfield	director, officer: President & CEO	C/O KYTHERA BIOPHARMACEUTICALS, INC. 27200 WEST AGOURA ROAD, SUITE 200 CALABASAS CA 91301
Paul F. Lizzul	officer: Chief Medical Officer	30699 RUSSELL RANCH ROAD, SUITE 140, WESTLAKE VILLAGE CA 91362
Diane Stroehmann	officer: See Remarks	30699 RUSSELL RANCH ROAD SUITE 140 WESTLAKE VILLAGE CA 91362
Dennis M Fenton	director
Todd Harris	director	30699 RUSSELL RANCH ROAD, SUITE 140, WESTLAKE VILLAGE CA 91362
Kristina Burow	director, 10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Robert J More	director	680 S CACHE STREET, SUITE 100, BOX 10820, JACKSON WY 83001
James M. Hindman	director	2525 DUPONT DRIVE, IRVINE CA 92612
Keith R Leonard	director	ARYX THERAPEUTICS,INC., 6300 DUMBARTON CIRCLE, FREMONT CA 94555
Arch Venture Partners Viii, L.p.	10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Fund Viii Overage, L.p.	10 percent owner	C/O ARCH VENTURE PARTNERS VIII, LLC, 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Fund X Overage, L.p.	10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Partners X Overage, L.p.	10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631